ログイン 会員登録
icon_bulk_order一括注文 Acrobiosystems for English
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z 0-9
phone
Your Position: ホーム > Protein > IL-17A > ILA-H5243

Human IL-17A / CTLA-8 Protein, His Tag (HPLC verified)

  • Synonym
    IL-17A,Interleukin-17A,CTLA-8,IL-17
  • Source
    Human IL-17A Protein, His Tag(ILA-H5243) is expressed from human 293 cells (HEK293). It contains AA Gly 24 - Ala 155 (Accession # Q16552-1).
    Predicted N-terminus: His
  • Molecular Characterization
    IL-17A Structure

    This protein carries a polyhistidine tag at the N-terminus.

    The protein has a calculated MW of 17.0 kDa. The protein migrates as 17-20 kDa and 22-25 kDa when calibrated against Star Ribbon Pre-stained Protein Marker under reducing (R) condition (SDS-PAGE) due to glycosylation.

  • Endotoxin
    Less than 1.0 EU per μg by the LAL method.
  • Purity

    >95% as determined by SDS-PAGE.

    >90% as determined by SEC-HPLC.

  • Formulation

    Lyophilized from 0.22 μm filtered solution in PBS, pH7.4 with trehalose as protectant.

    Contact us for customized product form or formulation.

  • Reconstitution

    Please see Certificate of Analysis for specific instructions.

    For best performance, we strongly recommend you to follow the reconstitution protocol provided in the CoA.

  • Storage

    For long term storage, the product should be stored at lyophilized state at -20°C or lower.

    Please avoid repeated freeze-thaw cycles.

    This product is stable after storage at:

    1. -20°C to -70°C for 12 months in lyophilized state;
    2. -70°C for 3 months under sterile conditions after reconstitution.
SDS-PAGE
IL-17A SDS-PAGE

Human IL-17A Protein, His Tag on SDS-PAGE under reducing (R) condition. The gel was stained with Coomassie Blue. The purity of the protein is greater than 95% (With Star Ribbon Pre-stained Protein Marker).

SEC-HPLC
IL-17A SEC-HPLC

The purity of Human IL-17A Protein, His Tag (Cat. No. ILA-H5243) was greater than 90% as determined by SEC-HPLC.

Bioactivity-ELISA
 IL-17A ELISA

Immobilized Human IL-17A Protein, His Tag (Cat. No. ILA-H5243) at 5 μg/mL (100 μL/well) can bind Monoclonal Anti-Human IL17A Antibody, Human IgG1 with a linear range of 0.2-2 ng/mL (QC tested).

 IL-17A ELISA

Immobilized Human IL-17A Protein, His Tag (Cat. No. ILA-H5243) at 5 μg/mL (100 μL/well) can bind Biotinylated Human IL-17 RA, His,Avitag (Cat. No. ILR-H82E5) with a linear range of 0.3-5 ng/mL (Routinely tested).

Bioactivity-SPR
 IL-17A SPR

Human IL-17 RA Protein, Fc Tag (Cat. No. ILA-H525f) captured on Protein A Chip can bind Human IL-17A Protein, His Tag (Cat. No. ILA-H5243) with an affinity constant of 0.360 nM as determined in a SPR assay (Biacore 8K) (Routinely tested).

  • Background
    Interleukin-17A (IL-17A), also known as CTLA-8, is a 15-20 kDa glycosylated cytokine that plays an important role in anti-microbial and chronic inflammation. The six IL-17 cytokines (IL-17A-F) are encoded by separate genes but adopt a conserved cystine knot fold (1, 2). Mature cynomolgus monkey IL-17A shares 96% amino acid sequence identity with human IL-17A (3, 4). IL-17A is secreted by Th17 cells, gamma /δ T cells, iNKT cells, NK cells, LTi cells, neutrophils, and intestinal Paneth cells (2). It forms disulfide-linked homodimers as well as disulfide-linked heterodimers with IL-17F (5, 6). IL-17A exerts its effects through the transmembrane IL-17RA in complex with IL-17RC or IL-17RD (7, 8). Both IL-17RA and IL-17RC are required for responsiveness to heterodimeric IL-17A/F (7). IL-17A promotes protective mucosal and epidermal inflammation in response to microbial infection (9‑12). It induces chemokine production, neutrophil influx, and the production of antibacterial peptides (9‑11). IL-17A/F likewise induces neutrophil migration, but IL-17F does not (11). IL-17A additionally enhances the production of inflammatory mediators by rheumatoid synovial fibroblasts and contributes to TNF-alpha induced shock (4, 13). In contrast, it can protect against the progression of colitis by limiting chronic inflammation (12). IL-17A encourages the formation of autoreactive germinal centers and exacerbates the onset and progression of experimental models of autoimmunity (14, 15). IL-17A has been shown to exert either tumorigenic or anti-tumor effects (16, 17).
  • Clinical and Translational Updates

コメント (0)


ETD of in-stock products: 4 business days

価格(JPY) : 98,000

価格(JPY) : 646,800

プロモーション&展示



医薬品開発状況

  • Number of Launched Drugs:3 Details
  • Number of Drugs in Clinical Trials:29 Details
  • Latest Research Phase:Approved

データシート&ドキュメンテーション

DMF請求
DMF (Drug Master File)

関連製品一覧

新製品

お問い合わせ&コメント

This web search service is supported by Google Inc.

totopphone